Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentation at SITC 2026

SHANGHAI and HONG KONG, Nov. 9, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996. HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for. ..

Read full story on Pr Newswire Apac